Thermo Fisher Scientific extends Wisconsin clinical research lab

Published: 19-Jun-2024

The Middleton site expansion bolsters the company's analytical capabilities for biopharmaceuticals, inhaled therapeutics and device testing, protein characterisation, cell and gene therapy and mass spectrometry

The PPD clinical research business of Thermo Fisher Scientific Inc., has inaugurated a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. 

The new 72,500 sqft building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities, which falls under the umbrella of its clinical development and laboratory services. 

The President of analytical services and clinical research at Thermo Fisher Scientific, Leon Wyszkowski, commented: “As research in biopharmaceutical therapies continues to expand, we are excited to expand our overall capacity and capabilities in laboratory services to help our customers deliver therapies that meet the highest quality and safety standards for patients,”

“This USD $58m investment to expand the site is a testament to our dedication in supporting Thermo Fisher’s Mission of making the world healthier, cleaner and safer.” 


Bolstering analytical capabilities 

The GMP site offers analytical services for small molecules and biologics, such as biopharmaceuticals, inhaled therapeutics and device testing, protein characterisation, cell and gene therapy and mass spectrometry analysis for all phases of drug development. 

The GMP campus’ latest addition is a multi-use and flexible biosafety level 2 laboratory with a purpose-built liquid chromatography-mass spectrometry and protein characterisation space. 

As well as the laboratory addition, the site has two novel large molecular suites with pre and post-amplification labs and two large general use labs.

The expansion will add up to 350 scientists and laboratory support professionals to the team of 2300 employees working across the breadth of the campus. 

End-to-end laboratory services

Previously, Thermo Fisher began offering biosafety testing in its GMP portfolio of services at its Middleton facility. 

With this additional capability plus the novel laboratory buildings, the site offers a full complement of end-to-end laboratory services.

In addition to the GMP and bioanalytical labs in Middleton, Thermo Fisher’s clinical research laboratory business includes:

  • Bioanalytical, biomarker and vaccine sciences labs in Richmond, Virginia 
  • A GMP lab in Athlone, Ireland; 
  • Central labs and biomarker operations in Brussels, Belgium, Highland Heights, Kentucky and Singapore
  • Bioanalytical, biomarker, vaccine sciences and central labs in Suzhou, China. 


You may also like